西妥昔单抗联合GP方案治疗老年晚期非小细胞肺癌的疗效和安全性

目的探讨西妥昔单抗联合GP方案治疗老年晚期非小细胞肺癌的疗效和安全性。方法随机选取2009年6月～2011年12月收治的149例老年非小细胞肺癌患者作为研究对象,按照治疗方法随机分为对照组和观察组,对照组进行单纯GP方案治疗,观察组在对照组基础上给予西妥昔单抗治疗。21d为1个周期,两个周期后对两组疗效及不良反应进行评定。结果对照组和观察组治疗有效率和疾病控制率分别为48.61%、61.11%和66.23%、81.81%,两组比较差异具有统计学意义(P<0.05)。观察组患者疾病进展时间、中位生存时间、1年、2年生存率较对照组高,差异具有统计学意义(P<0.05)。两组主要不良反应主要表现为骨髓抑制和胃肠道反应,多为Ⅰ～Ⅱ级,差异无统计学意义(P>0.05)。观察组还表现出皮肤毒性等。结论西妥昔单抗联合GP方案治疗晚期非小细胞肺癌疗效显著,不良反应可耐受,值得临床推广使用。

Objective To explore the efficacy and safety of Cetuximab combined GP regimen in senile patients with no-small cell lung cancer （NSCLC）. Methods 149 patients with NSCLC were divided randomly into control group and observe group. Patients in the control group were treated with GP regimen. Patients in the therapy group were treated with Cetuximab combined GP regimen. The regime were repeated 21 days. All patients were treated 42 days. The response rate, disease controlled rate, time to progression, mean survival time and 1,2,3 year survival rate were analyzed and the toxicity were estimated in control group and observe group. Results The response rate and disease controlled rate in the observe group and control group were 48.61%, 61.11% and 66.23%, 81.81%, respectively （P〈0.05）. Time to progression, mean survival time and 1,2,3 year survival rate in observe group significantly enhanced than control group （P〈0.05）. Main side effects were inhibition on the bone marrow and Gastrointestinal reaction in two group （P〈0.05）. Conclusion Cetuximab combined GP regimen was effective on no-small cell lung cancer（NSCLC） and the side effects were tolerable.